Oxford Global w/ Dr Ana Leite

Join our Director of Bioinformatics, Dr Ana Liete, for a talk on data driven approaches for precision medicine.

The Oxford Global Pharma Data congress showcases success in FAIR data implementation, data analytics, AI/ML technologies, RWE generation, scaling up data storage and infrastructure, leveraging multi omic datasets and data management strategies to help elevate research.

Ana will give a talk on data driven approaches to precision medicine, including;

  • How different approaches can be used to analyse patient clinical, genetics and genomics data
  • Implementing AI-augmented workflows to uncover insights from patient level data

Event website →

Ana Leite

Director of Bioinformatics

Ana is responsible for leading the Product & Tech strategy for Precision Medicine at BenevolentAI, taking a patient centric approach to understand disease endotypes, mechanisms and targets. At BenevolentAI Ana also delivered a strategy for an end to end flow of Omics data, ensuring integration with the Knowledge Graph and long-term value of data assets according to FAIR principles. Prior to joining BenevolentAI Ana worked at GSK where she executed digital strategy and led bioinformatics research to drive target discovery strategies. Ana received her PhD in Computational and Systems Biology at MIT and completed her postdoctoral training at UCL Cancer Institute.

More Posts

You Might Also Like

Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022